Tiziana Life Sciences Ltd
NASDAQ:TLSA · NASDAQ Global Market
+$0.03 today
Vol 0.29M · Avg 0.21M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$18.4M -94.4% | -$9.5M +32.3% | -$14.0M -11.5% | -$12.6M +27.7% | -$17.4M | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $234.0K +136.2% | $99.1K +30.4% | $76.0K +82.7% | $41.6K -60.2% | $104.5K | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $0 | $0 | $0 | $0 | $0 | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | $3.1M +794.2% | -$441.1K +64.8% | -$1.3M -31.9% | -$948.9K -65.6% | -$573.0K | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | -$692.0K +37.7% | -$1.1M +2.7% | -$1.1M -798.6% | -$127.2K -140.1% | $317.3K | $592.6M | $1.3B | $626.2M |
| Inventory | $0 | $0 | $0 | $0 | $0 | $1.0B | $1.2B | $1.1B |
| Accounts Payables | $0 | $0 | $0 | $0 | $0 | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | $3.8M +459.9% | $670.4K +713.9% | -$109.2K +86.7% | -$821.7K +7.7% | -$890.3K | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | $2.3M -73.4% | $8.6M +212.5% | $2.8M +208.8% | -$2.5M -249.3% | $1.7M | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | -$12.8M -953.5% | -$1.2M +90.2% | -$12.4M +22.3% | -$16.0M +0.9% | -$16.1M | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | -$21.0K -38.3% | -$15.2K | $0 | $0 +100.0% | -$16.3K | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | $0 | $0 | $0 | $0 | $0 | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | $0 +100.0% | -$52.0K +93.4% | -$791.4K +63.7% | -$2.2M | $0 | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $0 | $0 | $0 | $0 | $0 | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | $3.1M +29229.0% | $10.4K +105.2% | -$200.2K +81.4% | -$1.1M -1055.0% | $112.7K | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | $3.0M +5463.5% | -$56.7K +94.3% | -$991.6K +69.6% | -$3.3M -3480.4% | $96.4K | $4.8B | $6.4B | $5.1B |
| Debt Repayment | $0 +100.0% | -$141.0K | $0 | $0 | $0 | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $10.2M +174.8% | $3.7M +2850.6% | $125.8K | $0 -100.0% | $95.6K | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | -$196.0K -791.9% | $28.3K +130.1% | -$94.2K -110.0% | -$44.8K +60.2% | -$112.7K | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | $10.0M +178.0% | $3.6M +11272.7% | $31.7K +170.6% | -$44.8K -163.0% | -$17.0K | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | $84.0K +128.6% | -$293.3K -1223.6% | -$22.2K +93.2% | -$324.4K +78.8% | -$1.5M | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | $286.0K -85.9% | $2.0M +115.1% | -$13.4M +31.7% | -$19.6M -11.5% | -$17.6M | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | -$12.9M -942.3% | -$1.2M +90.1% | -$12.4M +22.3% | -$16.0M +1.0% | -$16.1M | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Immix Biopharma, Inc.
NASDAQ:IMMX
$509.75M
Zentalis Pharmaceuticals, Inc.
NASDAQ:ZNTL
$264.46M
MacroGenics, Inc.
NASDAQ:MGNX
$260.93M
Whitehawk Therapeutics Inc
NASDAQ:WHWK
$214.13M
Coya Therapeutics, Inc.
NASDAQ:COYA
$89.04M
Pliant Therapeutics, Inc.
NASDAQ:PLRX
$71.21M
eXoZymes, Inc.
NASDAQ:EXOZ
$62.62M
OKYO Pharma Limited
NASDAQ:OKYO
$60.62M
Estrella Immunopharma, Inc.
ESLA
$43.68M
Anebulo Pharmaceuticals, Inc.
ANEB
$15.92M
SEC Filings
Recent regulatory filings
No filings found.
Does TLSA generate free cash flow?
Tiziana Life Sciences Ltd (TLSA) generated -$12,868,000.00 of free cash flow in fiscal 2025.
How much operating cash flow does TLSA produce?
Operating cash flow was -$12,847,000.00, before capital expenditures of $21,000.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.